Celiac Disease Drug Market

Global Celiac Disease Drug Market Size, Share and Trend Analysis Report, By Drugs (First Line of Treatment and Second Line of Treatment), Forecast (2022-2028)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026173 | Category : Pharmaceuticals | Delivery Format: /

The global celiac disease drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Celiac disease is an autoimmune disorder in which a protein called gluten damages the small intestine's membrane. Gluten can be present in grains such as rye, barley, and wheat. Gluten causes an immunological reaction that damages the villi in the small intestine (small finger-like projections in the small intestine which promote absorption). The body's ability to absorb proteins, nutrients, lipids, vitamins, carbs, and minerals is hampered by the damage. This eventually leads to malnutrition. It causes neurological malfunction, infertility, osteoporosis, and anemia if left untreated. Men and women of various ages and races are affected by celiac disease. HLA DQ2 and HLA DQ8 are two of the most critical genes linked to celiac disease. About 30% of the world's population carries one or both genes, however, only one in every 30 people will acquire the condition. Screening and biopsy are used to diagnose the condition. It is estimated that 80% of celiac disease cases go undetected or are misdiagnosed as another disease.

The key players operating in the global celiac disease drug market include Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease announced the initiation of the Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as 'Non-Responsive Celiac Disease' (NRCD). Moreover, in November 2019, Bristol-Myers Squibb Co., has announced the acquisition of Celgene Corporation, a company that works in celiac disease treatment. This acquisition expands the product portfolio for Bristol company.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Drugs

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Pfizer Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Co., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Celiac Disease Drug Market Report by Segment

By Drugs

  • First Line of Treatment
  • Second Line of Treatment

Global Celiac Disease Drug Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa